It is thought that the poor prognosis caused by FLT3-ITD mutation was offset in non-hypocellular AML patients, because those were relatively younger and had undergone more allogeneic hematopoietic stem cell transplants than hypocellular AML patients. Here, FLT3 is linked to acute myeloid leukemia.